TDP-43 Transgenic Mouse Model Development Service

Are you currently facing long drug development cycles and challenges in identifying effective therapies for complex neurodegenerative diseases like amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD-TDP)? Our TDP-43 Transgenic Mouse Models service helps you accelerate drug discovery and obtain high-fidelity preclinical data through advanced transgenic model development and comprehensive phenotyping platforms.

TDP-43 proteinopathies represent a critical area in neurodegenerative research, characterized by the abnormal aggregation and mislocalization of TDP-43. This pathology is a hallmark of nearly all ALS cases and a significant portion of FTLD, alongside its presence in other neurodegenerative conditions. Understanding these complex mechanisms requires robust in vivo models. TDP-43 transgenic mouse models serve as indispensable tools, recapitulating key pathological and phenotypic features, thereby accelerating the discovery and validation of novel therapeutic strategies.

How Our TDP-43 Transgenic Mouse Models Can Assist Your Project?

At Creative Biolabs, we provide a robust platform for evaluating therapeutic candidates against TDP-43 proteinopathies. Our services offer precise insights into disease mechanisms and compound efficacy, delivering actionable data to drive your research forward. Clients can expect clearly defined deliverables and expert guidance throughout their project.

Discover How We Can Help - Request a Consultation

Workflow:

• Required Starting Materials:

To initiate your project, clients typically provide:

1. A detailed Project Scope outlining specific research objectives and desired outcomes.
2. Compound Information including mechanism of action, dosing regimens, and safety data (if testing therapeutic agents).
3. Specific Research Questions to guide model selection and study design.

• Final Deliverables:

Upon completion of your project, you will receive:

1. A Comprehensive Study Report detailing all experimental procedures, results, and conclusions.
2. Raw Data Files from all assessments, ensuring transparency and enabling further analysis.
3. High-Resolution Histological Images demonstrating TDP-43 pathology, neuroinflammation, and neuronal health.

• Estimated Timeframe:

The typical timeframe for a TDP-43 transgenic mouse model study ranges from 12 to 24 weeks, depending on the complexity of the study design, the specific model chosen (e.g., rapidly vs. slower progressing models), and the number of desired readouts.

Why Choose Us?

CBL stands at the forefront of neurodegenerative disease research, offering unparalleled expertise and a commitment to accelerating your therapeutic discoveries. Our TDP-43 transgenic mouse models are meticulously characterized and our study execution is rigorously controlled, ensuring the highest quality and most translational data.

Experience the CBL Advantage - Get a Quote Today

TDP-43 Transgenic Mouse Models

The complexity and progressive nature of TDP-43 proteinopathies necessitate sophisticated in vivo models that accurately recapitulate human disease pathology and phenotypes. TDP-43 transgenic mouse models have emerged as invaluable tools:

• Elucidate Disease Mechanisms: Investigate the precise molecular and cellular pathways through which aberrant TDP-43 drives neurodegeneration.
• Identify and Validate Therapeutic Targets: Pinpoint novel proteins or pathways that, when modulated, can halt or reverse disease progression.
• Conduct Preclinical Drug Efficacy Studies: Rigorously test potential therapeutic compounds before advancing them to costly human clinical trials.

Fig.1 Neurofilament light chain (NfL) levels in the plasma of human TDP-43(Q33K) transgenic mice.

Customer Reviews

"[Accelerated Discovery] Using CBL's TDP-43 Transgenic Mouse Models in our research has significantly improved the speed at which we can screen and validate potential therapeutic compounds. The reproducible motor deficits in the TAR4/4 model allowed for rapid assessment of our lead candidates." [March 2025], Dr. A***n S.

"[Unparalleled Insights] The detailed histopathological analysis, particularly the punctate p-TDP-43 aggregates and neuroinflammation markers, provided by CBL's team using the rNLS8 model was instrumental in understanding the precise mechanism of action of our drug. Their electrophysiology data on NCV and CMAP also offered critical functional validation." [February 2025], Dr. M***a K.

"[Reliable Partnership] CBL's flexibility in custom study design and their commitment to providing non-transgenic littermates as controls ensured the scientific rigor of our study. Their expertise in TDP-43(Q331K) models allowed us to investigate specific genetic aspects of FTLD-TDP with confidence." [April 2025], Dr. J***s L.

What We Can Offer?

At CBL, our TDP-43 transgenic mouse models service is designed to provide comprehensive, high-quality, and customizable solutions for your neurodegenerative disease research. We are committed to delivering exceptional results that accelerate your path to discovery.

• Extensive Model Portfolio: Access to a diverse range of well-characterized TDP-43 transgenic mouse models, including rNLS8 (Off Dox/Low Dox), TAR4/4, TAR6/6, TDP-43(WT), and TDP-43(Q331K), allowing for precise selection based on your research needs.
• Customized Study Design & Execution: Flexible and tailored study protocols to accommodate unique research objectives, compound characteristics, and desired readouts, ensuring optimal experimental design and efficiency.
• Comprehensive Phenotypic Characterization: Advanced assessment capabilities covering motor function, cognitive behavior, social interaction, and detailed electrophysiological measurements (NCV, CMAP) to capture the full spectrum of disease progression.
• In-depth Pathological Analysis: Robust histopathological and biochemical evaluations, including precise quantification of TDP-43 mislocalization, aggregation, phosphorylation, neuroinflammation, neuronal loss, and brain atrophy.
• Reproducible & Translational Data: Our meticulous adherence to established protocols and quality control measures ensures highly reproducible data with strong translational relevance to human TDP-43 proteinopathies.
• Expert Consultation & Support: Partner with our team of seasoned biology specialists who provide guidance from initial consultation through final data interpretation, ensuring a seamless and productive research experience.

Related Services

To further support your neurodegenerative disease research, CBL offers a suite of complementary services and products:

• Neuroinflammation Analysis: Leverage our advanced capabilities for quantifying neuroinflammatory markers in various biological samples, providing deeper insights into disease progression and drug effects.
• Custom Transgenic Model Generation: If your research requires a unique model not currently in our portfolio, our team can assist in generating custom transgenic lines tailored to your specific needs.
• In Vitro ALS Models: Complement your in vivo studies with our advanced in vitro platforms, including iPSC-derived motor neuron cultures and co-culture systems, for high-throughput screening and mechanistic investigations.

At CBL, we are committed to being your trusted partner in accelerating neurodegenerative disease research. Our expertise in TDP-43 transgenic mouse models, coupled with our comprehensive service offerings, ensures that your projects yield high-quality, translational data.

Contact Our Team for More Information and to Discuss Your Project.